◎ Sugi Atlas

Atlas / Disease / Respiratory failure

Respiratory failure

disease
On this page

Also known as acute and chronic respiratory failureacute respiratory failurechronic respiratory failurefailure, respiratory

Summary

Respiratory failure (MONDO:0021113) is a disease with 6 cohort genes (56 GWAS associations across 31 studies) and 888 clinical trials. Top therapeutic interventions include oxygen, norepinephrine, and thiamine ion.

At a glance

  • Cohort genes: 6
  • GWAS associations: 56
  • ClinVar variants: 6
  • Clinical trials: 888

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namerespiratory failure
Mondo IDMONDO:0021113
EFOEFO:0009686
MeSHD012131
DOIDDOID:11162
ICD-11370028006
NCITC26872
SNOMED CT39871006
UMLSC1145670
MedGen257837
Is cancer (heuristic)no

Also known as: acute and chronic respiratory failure · acute respiratory failure · chronic respiratory failure · failure, respiratory · respiratory failure

Data availability: 6 ClinVar variants · 56 GWAS associations (31 studies).

Disease family

An umbrella term covering 2 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › lower respiratory tract disorder › lung disorder › respiratory failure

Related subtypes (32): aspiration pneumonia, lung abscess, pneumonic plague, pulmonary alveolar proteinosis, pulmonary systemic sclerosis, obstructive lung disease, bronchiolitis, pulmonary immaturity, rheumatoid arthritis-associated interstitial lung disease, pulmonary embolism and infarction, acute chest syndrome, fungal lung infectious disease, middle lobe syndrome, pulmonary coin lesion, pulmonary plasma cell granuloma, silo filler disease, pulmonary alveolar microlithiasis, pulmonary venoocclusive disease, acute lung injury, interstitial lung disease, hantavirus pulmonary syndrome, pulmonary non-tuberculous mycobacterial infection, lung neoplasm, occupational lung disease, Wilson-Mikity syndrome, neonatal aspiration syndrome, pneumonitis, vanishing lung syndrome, restrictive pulmonary disease, shrinking lung syndrome, dystrophic pulmonary ossification, pulmonary artery disease

Subtypes (2): acute respiratory failure, respiratory paralysis

Genetics & variants

GWAS landscape

56 GWAS associations across 31 studies. Top hits map to 25 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs350813256e-72LZTFL1T1.66
rs730644253e-30LZTFL1T2.34
rs558536981e-24CHRNA5T0.08
rs21090692e-23DPP9A1.27
rs357319122e-21LZTFL1T1.78
rs124619642e-21CYP2F2P - CYP2A6A0.08
rs174862788e-21CHRNA5A0.08
rs130507282e-19IFNAR2-IL10RB, IFNAR2T1.16
chr15:788961293e-17A0.08
rs22698998e-14OAS3C0.84
rs357059508e-13MUC5AC - MUC5BG0.09
rs1433341432e-12CCHCR1A1.29
rs5590561882e-12RDX, LINC02715T2.21
rs5681122635e-12LINC02392 - LINC02822C2.51
rs18190403e-11KANSL1A0.88
rs110857274e-11TYK2T1.18
chr20:619927004e-11G0.06
rs110857251e-10TYK2T1.27
rs107746711e-10OAS1G0.9
rs5059222e-10ABOC1.1
rs6872894e-10ABOA1.24
chr14:246655662e-09A2.31
rs785311333e-09DSTA1.67
rs95012574e-09HLA-DPB1G1.24
rs775345762e-08TAC4-AS1 - RNU6-1313PT1.44
rs5500572e-08ABOT1.19
chr9:50737702e-08T1.13
rs14056553e-08NR1H2C1.09
rs126104953e-08DPP9G1.29
rs18868144e-08FOXP4-AS1C1.24

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90476035Verma A202432,246399,549Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90476036Verma A202424,849411,900Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90278684Degenhardt F202214,4671,306,293Detailed stratified GWAS analysis for severe COVID-19 in four European populations.
GCST90473742UK Biobank Whole-Genome Sequencing Consortium20258,637449,803Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90667932UK Biobank Whole-Genome Sequencing Consortium20258,637449,803Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90478169Verma A20247,281109,873Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480266Verma A20247,281109,873Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90278686Degenhardt F20226,526719,075Detailed stratified GWAS analysis for severe COVID-19 in four European populations.
GCST90478171Verma A20245,862112,646Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480262Verma A20245,862112,646Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding1
Tier 2: splice/UTR4
Tier 3: regulatory0
Tier 4: intronic/intergenic38

MAF distribution

BucketVariants
common (>=0.05)30
low_freq (0.01-0.05)7
rare (<0.01)2
unknown4

Functional consequences

ConsequenceCount
intron_variant28
unknown6
intergenic_variant4
5_prime_UTR_variant1
splice_region_variant1
splice_acceptor_variant1
3_prime_UTR_variant1
missense_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs35081325345848429A>G,T0.085intron_variantLZTFL16e-72Tier 4: intronic/intergenic
rs73064425345859597C>T0.084intron_variantLZTFL13e-30Tier 4: intronic/intergenic
rs558536981578565597T>G0.3355_prime_UTR_variantCHRNA51e-24Tier 2: splice/UTR
rs2109069194719431G>A0.323intron_variantDPP92e-23Tier 4: intronic/intergenic
rs35731912345848457C>T0.081intron_variantLZTFL12e-21Tier 4: intronic/intergenic
rs124619641940835324A>G,T0.474intron_variantCYP2F2P - CYP2A62e-21Tier 4: intronic/intergenic
rs174862781578575140A>C0.32intron_variantCHRNA58e-21Tier 4: intronic/intergenic
rs130507282133242905T>A,C0.355intron_variantIFNAR2-IL10RB, IFNAR22e-19Tier 4: intronic/intergenic
chr15:788961290.343e-17Tier 4: intronic/intergenic
rs226989912112944151C>T0.334intron_variantOAS38e-14Tier 4: intronic/intergenic
rs35705950111219991G>A,T0.11splice_region_variantMUC5AC - MUC5B8e-13Tier 2: splice/UTR
rs143334143631153649G>A0.106intron_variantCCHCR12e-12Tier 4: intronic/intergenic
rs55905618811110029398T>A0.001intron_variantRDX, LINC027152e-12Tier 4: intronic/intergenic
rs5681122631290486677C>A,G0.001intergenic_variantLINC02392 - LINC028225e-12Tier 4: intronic/intergenic
rs18190401746142465T>A,C,G0.175intron_variantKANSL13e-11Tier 4: intronic/intergenic
rs110857271910355447C>T0.28intron_variantTYK24e-11Tier 4: intronic/intergenic
chr20:619927000.2084e-11Tier 4: intronic/intergenic
rs110857251910351837C>G,T0.264intron_variantTYK21e-10Tier 4: intronic/intergenic
rs1077467112112919388G>A,C0.324splice_acceptor_variantOAS11e-10Tier 2: splice/UTR
rs5059229133273813C>T0.352intron_variantABO2e-10Tier 4: intronic/intergenic
rs6872899133261703A>C,G,T0.348intron_variantABO4e-10Tier 4: intronic/intergenic
chr14:246655662e-09Tier 4: intronic/intergenic
rs78531133656842705G>A0.03intron_variantDST3e-09Tier 4: intronic/intergenic
rs9501257633087578A>C,G,T0.0783_prime_UTR_variantHLA-DPB14e-09Tier 2: splice/UTR
rs775345761749863303C>T0.034intergenic_variantTAC4-AS1 - RNU6-1313P2e-08Tier 4: intronic/intergenic
rs5500579133271182T>A,C0.274intron_variantABO2e-08Tier 4: intronic/intergenic
chr9:50737702e-08Tier 4: intronic/intergenic
rs14056551950379362T>A,C,G0.323intron_variantNR1H23e-08Tier 4: intronic/intergenic
rs12610495194717660A>G,T0.259intron_variantDPP93e-08Tier 4: intronic/intergenic
rs1886814641534945A>C0.044intron_variantFOXP4-AS14e-08Tier 4: intronic/intergenic

ClinVar germline variants

6 retrieved; paginated sample, class counts are floors:

3 pathogenic, 2 uncertain significance, 1 pathogenic/likely pathogenic

ClinVarVariant (HGVS)GeneClassificationReview
400NM_019892.6(INPP5E):c.1132C>T (p.Arg378Cys)INPP5EPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
1299473NM_001284401.2(TAMM41):c.329A>G (p.Tyr110Cys)TAMM41Pathogenicno assertion criteria provided
1299474NM_001284401.2(TAMM41):c.806dup (p.Asn269fs)TAMM41Pathogenicno assertion criteria provided
1192322NM_005427.4(TP73):c.613G>T (p.Glu205Ter)TP73Pathogeniccriteria provided, single submitter
318546NM_001089.3(ABCA3):c.1336G>A (p.Asp446Asn)ABCA3Uncertain significancecriteria provided, multiple submitters, no conflicts
1339481NM_002204.4(ITGA3):c.1766G>C (p.Arg589Pro)ITGA3Uncertain significancecriteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 11 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
TP73Orphanet:70573Small cell lung cancer
PMPCAOrphanet:1170Autosomal recessive cerebelloparenchymal disorder type 3
INPP5EOrphanet:1454Joubert syndrome with hepatic defect
INPP5EOrphanet:220493Joubert syndrome with ocular defect
INPP5EOrphanet:475Isolated Joubert syndrome
INPP5EOrphanet:75858MORM syndrome
ABCA3Orphanet:2032Idiopathic pulmonary fibrosis
ABCA3Orphanet:217563Neonatal acute respiratory distress syndrome
ABCA3Orphanet:440402Interstitial lung disease due to ABCA3 deficiency
ABCA3Orphanet:685082Pediatric acute respiratory distress syndrome
ITGA3Orphanet:306504Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome

Cohort genes → proteins

6 cohort genes, 6 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence6

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
TP73HGNC:12003ENSG00000078900O15350Tumor protein p73clinvar
PMPCAHGNC:18667ENSG00000165688Q10713Mitochondrial-processing peptidase subunit alphaclinvar
INPP5EHGNC:21474ENSG00000148384Q9NRR6Phosphatidylinositol polyphosphate 5-phosphatase type IVclinvar
TAMM41HGNC:25187ENSG00000144559Q96BW9Phosphatidate cytidylyltransferase, mitochondrialclinvar
ABCA3HGNC:33ENSG00000167972Q99758Phospholipid-transporting ATPase ABCA3clinvar
ITGA3HGNC:6139ENSG00000005884P26006Integrin alpha-3clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
TP73Tumor protein p73Participates in the apoptotic response to DNA damage.
PMPCAMitochondrial-processing peptidase subunit alphaSubstrate recognition and binding subunit of the essential mitochondrial processing protease (MPP), which cleaves the mitochondrial sequence off newly imported precursors proteins.
INPP5EPhosphatidylinositol polyphosphate 5-phosphatase type IVPhosphatidylinositol (PtdIns) phosphatase that specifically hydrolyzes the 5-phosphate of phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3), phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) and phosphatidylinositol 3,5-bispho…
TAMM41Phosphatidate cytidylyltransferase, mitochondrialCatalyzes the conversion of phosphatidic acid (PA) to CDP-diacylglycerol (CDP-DAG), an essential intermediate in the synthesis of phosphatidylglycerol, cardiolipin and phosphatidylinositol.
ABCA3Phospholipid-transporting ATPase ABCA3Catalyzes the ATP-dependent transport of phospholipids such as phosphatidylcholine and phosphoglycerol from the cytoplasm into the lumen side of lamellar bodies, in turn participates in the lamellar bodies biogenesis and homeostasis of pul…
ITGA3Integrin alpha-3Integrin alpha-3/beta-1 is a receptor for fibronectin, laminin, collagen, epiligrin, thrombospondin and CSPG4.

Protein-family classification

Druggable: 4 · Difficult: 1 · Unknown: 1 · Druggable fraction: 0.67

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Transporter113.0×0.377
Protease16.1×0.377
Antibody/Immunoglobulin14.9×0.377
Enzyme (other)12.0×0.610
Transcription factor11.4×0.647
Other/Unknown10.3×0.993

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
TP73Transcription factornoSAM, p53_tumour_suppressor, p53-like_TF_DNA-bd_sf
PMPCAProteaseyes3.4.24.64Pept_M16_Zn_BS, Peptidase_M16_C, Metalloenz_LuxS/M16
INPP5EEnzyme (other)yes3.1.3.36IPPc, Endo/exonu/phosph_ase_sf, INPP5E
TAMM41Other/UnknownnoTam41
ABCA3TransporteryesABC_transporter-like_ATP-bd, AAA+_ATPase, ABC2_TM
ITGA3Antibody/ImmunoglobulinyesIntegrin_alpha, FG-GAP, Int_alpha_beta-p

Expression context

Cohort genes with no expression data: 0.

4 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)6
unknown0

Top tissues across cohort

TissueCohort genes
right uterine tube2
upper lobe of left lung2
olfactory segment of nasal mucosa1
pancreatic ductal cell1
adrenal tissue1
apex of heart1
right lobe of liver1
oocyte1
secondary oocyte1
granulocyte1
male germ line stem cell (sensu Vertebrata) in testis1
primordial germ cell in gonad1
lower lobe of lung1
upper lobe of lung1
metanephric glomerulus1
right coronary artery1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
TP73132broadmarkerright uterine tube, olfactory segment of nasal mucosa, pancreatic ductal cell
PMPCA276ubiquitousmarkerright lobe of liver, adrenal tissue, apex of heart
INPP5E279ubiquitousyesright uterine tube, secondary oocyte, oocyte
TAMM41136ubiquitousyesprimordial germ cell in gonad, granulocyte, male germ line stem cell (sensu Vertebrata) in testis
ABCA3222ubiquitousmarkerlower lobe of lung, upper lobe of lung, upper lobe of left lung
ITGA3149ubiquitousmarkermetanephric glomerulus, right coronary artery, upper lobe of left lung

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
PMPCA3,679
TP732,320
ITGA32,079
ABCA31,436
INPP5E1,309
TAMM41869

Structural data

PDB: 3 · AlphaFold-only: 3 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
TP73O1535028
ABCA3Q997582
INPP5EQ9NRR61

AlphaFold-only cohort genes (top 30 by pLDDT)

SymbolUniProtpLDDT
PMPCAQ1071388.46
ITGA3P2600683.88
TAMM41Q96BW973.42

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 44. Enrichment computed across 6 evidence-associated genes (5 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 5 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Defective ABCA3 causes SMDP312284.0×0.010ABCA3
ARL13B-mediated ciliary trafficking of INPP5E1761.3×0.019INPP5E
Diseases associated with surfactant metabolism1571.0×0.019ABCA3
Activation of PUMA and translocation to mitochondria1228.4×0.027TP73
TP53 Regulates Transcription of Caspase Activators and Caspases1190.3×0.027TP73
TP53 Regulates Transcription of Death Receptors and Ligands1190.3×0.027TP73
Regulation of TP53 Activity through Association with Co-factors1163.1×0.027TP73
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain1152.3×0.027TP73
Synthesis of PIPs at the Golgi membrane1126.9×0.027INPP5E
Processing of SMDT11126.9×0.027PMPCA
ABC transporters in lipid homeostasis1120.2×0.027ABCA3
MET promotes cell motility1120.2×0.027ITGA3
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release1108.8×0.027TP73
Mitochondrial calcium ion transport1108.8×0.027PMPCA
Basigin interactions187.8×0.029ITGA3
ABC transporter disorders187.8×0.029ABCA3
Laminin interactions176.1×0.029ITGA3
MET activates PTK2 signaling176.1×0.029ITGA3
Surfactant metabolism173.7×0.029ABCA3
PI Metabolism171.4×0.029INPP5E
Transport of small molecules210.1×0.029PMPCA, ABCA3
Signaling by MET163.4×0.030ITGA3
Cargo trafficking to the periciliary membrane149.6×0.037INPP5E
Phospholipid metabolism140.1×0.043INPP5E
Protein localization138.1×0.044PMPCA
Mitochondrial protein import133.6×0.048PMPCA
Disorders of transmembrane transporters127.9×0.056ABCA3
Integrin cell surface interactions126.9×0.056ITGA3
ABC-family protein mediated transport124.3×0.059ABCA3

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 6 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
response to xenobiotic stimulus334.5×0.005TP73, ABCA3, ITGA3
positive regulation of protein homooligomerization12808.7×0.008ABCA3
regulation of phosphatidylcholine metabolic process11404.3×0.008ABCA3
positive regulation of lung ciliated cell differentiation11404.3×0.008TP73
positive regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator11404.3×0.008TP73
negative regulation of cell projection organization1936.2×0.008ITGA3
response to gonadotropin1936.2×0.008ITGA3
xenobiotic export from cell1936.2×0.008ABCA3
renal filtration1936.2×0.008ITGA3
negative regulation of protein localization to cilium1936.2×0.008INPP5E
lung development266.1×0.008ABCA3, ITGA3
cerebrospinal fluid secretion1702.2×0.009TP73
response to inositol1702.2×0.009INPP5E
positive regulation of phospholipid efflux1702.2×0.009ABCA3
cardiolipin biosynthetic process1561.7×0.010TAMM41
regulation of lipid biosynthetic process1468.1×0.011ABCA3
organelle assembly1468.1×0.011ABCA3
positive regulation of phospholipid transport1401.2×0.012ABCA3
obsolete protein processing involved in protein targeting to mitochondrion1351.1×0.013PMPCA
negative regulation of cardiac muscle cell proliferation1312.1×0.013TP73
nephron development1312.1×0.013ITGA3
mesodermal cell differentiation1255.3×0.015ITGA3
phosphatidylglycerol metabolic process1234.1×0.015ABCA3
CDP-diacylglycerol biosynthetic process1216.1×0.015TAMM41
positive regulation of cell size1216.1×0.015TP73
dendritic spine maintenance1216.1×0.015ITGA3
regulation of BMP signaling pathway1200.6×0.016ITGA3
digestive tract morphogenesis1165.2×0.018TP73
phospholipid homeostasis1165.2×0.018ABCA3
xenobiotic transmembrane transport1156.0×0.018ABCA3

Therapeutics

Drugs indicated for this disease

1 approved, 13 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
Nitric OxideApproved (phase 4)
AlmitrinePhase 3 (in late-stage trials)
AzithromycinPhase 3 (in late-stage trials)
DexamethasonePhase 3 (in late-stage trials)
DexmedetomidinePhase 3 (in late-stage trials)
FentanylPhase 3 (in late-stage trials)
FospropofolPhase 3 (in late-stage trials)
HydroxychloroquinePhase 3 (in late-stage trials)
IsofluranePhase 3 (in late-stage trials)
MidazolamPhase 3 (in late-stage trials)
NitrogenPhase 3 (in late-stage trials)
PropofolPhase 3 (in late-stage trials)
SevofluranePhase 3 (in late-stage trials)
Testosterone UndecanoatePhase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Albuterol, Alteplase, Aspirin, Cholecalciferol, Clopidogrel, Etomidate, Fondaparinux, L-Citrulline, Lucinactant, Mefloquine, Morphine, Remifentanil, Tirofiban.

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 6

Druggability breadth: 2 of 6 evidence-associated genes (33%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
TP7300
PMPCA00
INPP5E00
TAMM4100
ABCA300
ITGA300

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 2.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
ITGA35Binding:5
PMPCA1Binding:1

Cohort enzymes (BRENDA EC)

SymbolEC numbersNames
PMPCA3.4.24.64mitochondrial processing peptidase
INPP5E3.1.3.36phosphoinositide 5-phosphatase

Pharmacogenomics

Cohort genes with a PharmGKB record: 6; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug2INPP5E, ABCA3
DDruggable family + AlphaFold only, no drug2PMPCA, ITGA3
EDifficult family or no structure, no drug2TP73, TAMM41

Undrugged target profiles

6 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
TP730—
PMPCA1—
INPP5E0—
TAMM410—
ABCA30—
ITGA35—

Clinical trials & evidence

Clinical trials

Clinical trials: 888.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified760
PHASE233
PHASE432
PHASE331
PHASE2/PHASE312
PHASE1/PHASE29
PHASE19
EARLY_PHASE12

Top trials by phase / activity

NCTPhaseStatusTitle
NCT04496362PHASE4ACTIVE_NOT_RECRUITINGVeno-venous Extracorporeal Membrane Oxygenation (VV-ECMO) Heparin Study
NCT06401083PHASE4RECRUITINGThe Effect of an Additional Pre-extubational Loading Dose of Caffeine-citrate
NCT06881927PHASE4NOT_YET_RECRUITINGEduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure
NCT00208078PHASE4TERMINATEDEffect of Non-Invasive Ventilation in Cystic Fibrosis Patient With Chronic Respiratory Failure.
NCT00291460PHASE4UNKNOWNInspiratory Muscle Training in Hypercapnic COPD
NCT00355732PHASE4COMPLETEDChronic Obstructive Pulmonary Disease and Weaning From Mechanical Ventilation in Difficult to Wean Patients
NCT00560287PHASE4UNKNOWNNon-Invasive Ventilation in Amyotrophic Lateral Sclerosis
NCT00600639PHASE4TERMINATEDNon-Invasive Mechanical Ventilation in Elderly Patients
NCT00698958PHASE4COMPLETEDAmbulatory Adaptation to Non-Invasive Mechanical Ventilation
NCT00708149PHASE4COMPLETEDComparison of the Efficacy for Stress Ulcer Prophylaxis Between the Patients Received Lansoprazole OD and Control Group Weaning From Mechanical Ventilator in Respiratory Care Center: a Randomized Control Trial
NCT00732537PHASE4COMPLETEDInhaled Nitric Oxide by Oxygen Hood in Neonates
NCT00925860PHASE4COMPLETEDNon-Positive Pressure Ventilation in Hypoxemic Patients
NCT01204281PHASE4COMPLETEDProportional Assist Ventilation (PAV) in Early Stage of Critically Ill Patients
NCT01280019PHASE4UNKNOWNFRC Guided Therapy in Acute Respiratory Failure
NCT01472302PHASE4COMPLETEDClosed Loop Ventilation Strategy in Intensive Care Unit (ICU) Patients
NCT01572337PHASE4COMPLETEDEarly Non-invasive Ventilation Outside the Intensive Care Unit
NCT01941524PHASE4COMPLETEDBrain Oxygenation and Function of Preterm Newborns During Administration of Two Different Surfactant Preparations
NCT02203019PHASE4COMPLETEDStudy of Sedative Medications in Patients With Severe Infection and Respiratory Failure
NCT02491346PHASE4UNKNOWNA Trial Comparing SGC and Conventional Empiric Treatment for Glucose Control in Critically Ill Patients With Mechanical Ventilation in ICU
NCT02497729PHASE4COMPLETEDChecklists and Upright Positioning in Endotracheal Intubation of Critically Ill Patients (Check-UP) Trial
NCT02526862PHASE4COMPLETEDPrevention of Pressure Ulcers in Patients Under Non-Invasive Mechanical Ventilation
NCT02958150PHASE4UNKNOWNDexmedetomidine Versus Standard Clinical Practice During Non Invasive Mechanical Ventilation
NCT03026777PHASE4COMPLETEDPreventing Cardiovascular collaPse With Administration of Fluid Resuscitation Before Endotracheal Intubation
NCT03337373PHASE4COMPLETEDThe Study of Pharmacokinetics and Pharmacodynamics of Cisatracurium
NCT03625687PHASE4TERMINATEDPan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant
NCT03787732PHASE4COMPLETEDPreventing Cardiovascular Collapse With Administration of Fluid Resuscitation During Induction and Intubation
NCT03962725PHASE4TERMINATEDAvoiding Neuromuscular Blockers to Reduce Complications
NCT04092621PHASE4UNKNOWNRapid Atrial Fibrillation Treatment Strategy
NCT04350086PHASE4WITHDRAWNUse of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection
NCT05277896PHASE4COMPLETEDRandomized Trial of Sedative Choice for Intubation
NCT05322447PHASE4COMPLETEDHigh-dose L-Carnitine and Diaphragmatic Function Assessed by Ultrasonography in Patients With Respiratory Failure.
NCT05843123PHASE4COMPLETEDComparison of Gas Exchange Between Two Invasive Mechanical Ventilation Modes in Children
NCT05014581PHASE3RECRUITINGPreventing Cardiovascular Collapse With Vasopressors During Tracheal Intubation
NCT05527704PHASE3ACTIVE_NOT_RECRUITINGthe Inhaled β2-adrenergic Receptor Agonist for Transient Tachypnoea of the Newborn (the REFSAL Trial)
NCT06066502PHASE3RECRUITINGPrecision Ventilation vs Standard Care for Acute Respiratory Distress Syndrome
NCT06503016PHASE3RECRUITINGThe Effect of phoSPHocreatine on mEdical Emergency Team (Met) tREated Patients
NCT06815679PHASE2/PHASE3NOT_YET_RECRUITINGPhysiological Effects of Nebulized Salbutamol in Acute Respiratory Failure Patients on HFNC
NCT00000562PHASE3COMPLETEDExtracorporeal Support for Respiratory Insufficiency (ECMO)
NCT00148642PHASE3COMPLETEDSilver-Coated Endotracheal Tube to Reduce Ventilator Associated Pneumonia (VAP)
NCT00221520PHASE3UNKNOWNSedation in the Intensive Care Unit

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
OXYGEN421
NOREPINEPHRINE45
THIAMINE ION44
AMIODARONE43
ETOMIDATE43
FONDAPARINUX43
CAFFEINE CITRATE42
CISATRACURIUM42
CLOPIDOGREL42
DEXMEDETOMIDINE42
ILOPROST42
NITROUS ACID42
SODIUM NITROPRUSSIDE42
ACYCLOVIR41
ALTEPLASE41
ARFORMOTEROL41
ARGATROBAN41
BERACTANT41
BIVALIRUDIN41
ESKETAMINE41
FENTANYL41
FORMOTEROL41
FUROSEMIDE41
HEPARIN41
HYDROXYCHLOROQUINE41
IPRATROPIUM BROMIDE41
MEFLOQUINE41
MODAFINIL41
NICARDIPINE41
PARATHYROID HORMONE41

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 70

This page pulls from 70 datasets indexed by BioBTree:

alphafoldantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsclinvarctd_gene_interactiondbsnpdepmapdiamond_similaritydoidefoensemblentrezesm2_similarityfantom5_genefantom5_promotergenccgenerifgogtopdbgtopdb_interactiongwasgwas_studyhgncicd11intactinterpromedgenmeshmimmondomondochildmondoparentncitorphanetpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assayreactomerefseqrhearnacentralsctidscxa_expressionscxa_gene_experimentsignorstring_interactiontranscriptufeatureumlsuniprot